Stock listing

NASDAQ:COYA Coya Therapeutics, Inc. Stock

Home listing (NASDAQ) of Coya Therapeutics, Inc.

Follow Coya Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:COYA

$2.95 USD -0.14 (-4.5%)

Close on Nov 20, 2026

Past year -50.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$2.90 – $3.11 USDNov 20, 2026
Volume
138,271 sharesNov 20, 2026
Market cap
$69.20M USDAt the close on Nov 20, 2026 · price × 23.46M shares outstanding
52-week range
$2.72 – $6.62 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$615,419 USDMedian day 129,572 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Coya Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:COYA · Home$2.95 USD-0.14 (-4.5%)138,271$2.94$3.11$2.90$3.09Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:COYA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$2.95-0.14-4.5%$2.94$3.11$2.90138,271
$3.09+0.07+2.3%$3.03$3.30$3.01150,403
$3.02+0.02+0.7%$2.99$3.12$2.93131,274
$3.00-0.13-4.2%$3.175$3.175$2.96299,179
$3.13-0.14-4.3%$3.25$3.25$3.02189,167
$3.27+0.06+1.9%$3.19$3.41$3.05141,124
$3.21+0.05+1.6%$3.29$3.39$3.1789,965
$3.16-0.17-5.1%$3.23$3.47$3.15200,524
$3.33+0.34+11.4%$3.00$3.38$2.925222,818
$2.99+0.18+6.4%$2.83$3.025$2.735230,567
$2.81-0.27-8.8%$3.03$3.14$2.72315,215
$3.08-0.03-1.0%$3.28$3.40$2.98195,395
$3.11-0.12-3.7%$3.26$3.405$3.03518,217
$3.23-0.38-10.5%$3.64$3.89$3.175270,174
$3.61-0.37-9.3%$3.96$4.085$3.594214,740
$3.98-0.08-2.0%$4.08$4.20$3.9570,105
$4.06-0.06-1.5%$4.09$4.175$4.045150,844
$4.12+0.17+4.3%$3.97$4.30$3.9455,827
$3.95+0.01+0.3%$3.95$4.03$3.91129,572
$3.94-0.20-4.8%$4.08$4.245$3.935188,644
$4.140.000.0%$4.09$4.43$4.0982,988
$4.14-0.07-1.7%$4.23$4.29$4.1095,099
$4.21+0.01+0.2%$4.22$4.38$4.2182,913
$4.20-0.05-1.2%$4.29$4.535$4.20106,480
$4.25-0.09-2.1%$4.37$4.39$4.16134,191
$4.34+0.16+3.8%$4.18$4.50$4.14236,556
$4.18-0.295-6.6%$4.645$4.645$4.16258,003
$4.475-0.335-7.0%$4.81$4.89$4.45207,772
$4.81-0.14-2.8%$5.00$5.05$4.81102,055
$4.95-0.04-0.8%$5.00$5.05$4.85151,829
$4.99+0.08+1.6%$4.91$5.00$4.70144,420
$4.91+0.06+1.2%$4.81$5.01$4.75595,511
$4.850.000.0%$4.86$5.03$4.7494,629
$4.85+0.04+0.8%$4.85$4.94$4.78117,247
$4.81+0.08+1.7%$4.80$4.93$4.7688,690
$4.73-0.28-5.6%$5.00$5.00$4.70116,132
$5.01-0.02-0.4%$5.06$5.15$4.98101,360
$5.03+0.05+1.0%$5.02$5.05$4.9375,465
$4.98-0.10-2.0%$5.03$5.12$4.96120,318
$5.08-0.10-1.9%$5.19$5.24$5.0259,938
$5.18+0.14+2.8%$5.02$5.18$4.92106,635
$5.04-0.26-4.9%$5.31$5.31$4.90158,612
$5.30+0.35+7.1%$4.99$5.35$4.93334,121
$4.95+0.06+1.2%$4.94$5.04$4.831167,197
$4.89+0.13+2.7%$4.76$5.085$4.705403,456
$4.76+0.30+6.7%$4.54$4.89$4.54221,539
$4.46-0.19-4.1%$4.66$4.719$4.46129,322
$4.65+0.01+0.2%$4.62$4.72$4.49215,172
$4.64+0.26+5.9%$4.39$4.78$4.33201,468
$4.38-0.14-3.1%$4.59$4.66$4.37139,342
$4.52-0.09-2.0%$4.61$4.62$4.45593,464
$4.610.000.0%$4.55$4.695$4.5377,819
$4.61-0.15-3.2%$4.82$4.82$4.59598,353
$4.76+0.21+4.6%$4.54$4.77$4.5275,759
$4.55+0.13+2.9%$4.50$4.58$4.36100,315
$4.42-0.09-2.0%$4.53$4.649$4.3961,902
$4.51-0.05-1.1%$4.52$4.63$4.48101,246
$4.56-0.03-0.7%$4.58$4.698$4.5147,432
$4.59-0.27-5.6%$4.82$4.82$4.55153,108
$4.86-0.01-0.2%$5.14$5.14$4.7677,622
$4.87-0.17-3.4%$5.02$5.03$4.8354,399
$5.04+0.08+1.6%$4.99$5.22$4.98145,185
$4.96+0.09+1.8%$4.89$5.26$4.71147,065
$4.87+0.01+0.2%$4.90$4.95$4.80570,948
$4.86-0.11-2.2%$5.00$5.00$4.7359,524
Ticker
NASDAQ:COYA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Coya Therapeutics, Inc. news

Coya Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
27 in the last 12 months · 105 in all · newest Nov 10, 2026 · oldest 2023
Decks
24 decks · latest October 2026

Where Coya Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:COYA · Home listing · This pageNASDAQUnited StatesUSD
BOATS:COYABOATSUnited StatesUSD

Valuation

EV/sales 7.1× against a median of 49.9×: 2nd lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$33.40M USD
P/E
Loss
EV/sales
7.1×
EV/EBITDA
Negative EBITDA
Price/book
2.1×
Gross margin
100.0%
Operating margin
−675.3%
Net margin
−643.5%
Debt to equity
0.0×
Beta vs S&P 500
1.64

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Coya Therapeutics, Inc. · NASDAQ:COYAUS$69.20MUS$33.40Mn/a7.1×n/a2.1×−643.5%0.0×1.64
Eastwood Bio-Medical Canada Inc · TSXV:EBMUS$72.06MUS$72.05Mn/a127×n/an/a−28.5%n/a0.56
SynAct Pharma AB · OMXSTO:SYNACTUS$71.20MUS$71.51Mn/an/an/a5.1×n/a0.3×n/a
Bioton S.A. · GPW:BIOUS$70.63MUS$86.88Mn/a1.4×6.5×0.5×−3.3%0.1×n/a
MAIA Biotechnology, Inc. · AMEX:MAIAUS$68.54MUS$68.54Mn/an/an/a4.7×n/a0.0×1.62
ABIONYX Pharma SA · EURONEXT:ABNXUS$68.36MUS$55.53Mn/a12.4×n/a4.0×−136.6%1.0×n/a
Cingulate Inc. · NASDAQ:CINGUS$67.48MUS$1.21Bn/an/an/a3.3×n/a56.0×1.41
Energenesis Biomedical Co., Ltd. · TWSE:6657US$67.22MUS$47.02Mn/a203×n/a3.1×n/a0.0×n/a
MediciNova, Inc. · NASDAQ:MNOVUS$67.11MUS$38.45Mn/a41.1×n/a1.6×n/a0.0×0.56
Dicot Pharma AB · OMXSTO:DICOTUS$66.56MUS$44.51Mn/an/an/a3.0×n/a0.0×n/a
Cardiff Oncology, Inc. · NASDAQ:CRDFUS$66.34MUS$32.82Mn/a58.7×n/a2.4×n/a0.0×1.32
Median of the othersUS$67.92MUS$62.04M49.9×6.5×3.1×−28.5%0.0×1.32

Forecasts

7 strong buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
15.21 USD · Analysts' mean
EPS, year to Dec 2026
-1.53 · 1 analyst
Revenue, year to Dec 2026
1.14M · 6 analysts

Team and board

Officers

OfficerRole
Arun SwaminathanChief Executive Officer
David SnyderChief Financial Officer & Chief Operating Officer
Fred GrossmanPresident & Chief Medical Officer
Daniel BarvinVice President of Operations & Patient Advocacy
Karen KingSenior VP of Program Management & Clinical Operations
Michelle FrazierSenior VP of Regulatory
Anabella VillalobosChief Scientific Officer at Metaphore Biotechnologies
Ann LeeChief Technical Officer at Prime Medicine

Board

DirectorRole
Dieter WeinandChairman of the Board of Directors
Mark PavaoDirector
Wilbur RossDirector

Events

QuarterResultsShare move
Q3 2026Nov 10, 2026 · Before open−5.1%
Q2 2026Aug 11, 2026 · Before open+3.5%
Q1 2026May 7, 2026−3.1%
Q4 2025Mar 16, 2026 · Before open−0.7%
Q3 2025Nov 12, 2025 · Before open+1.3%
Q2 2025Aug 12, 2025 · Before open−0.3%
Q1 2025May 13, 2025 · Before open−6.2%
Q4 2024Mar 18, 2025−5.8%
Q3 2024Nov 6, 2024 · Before open+7.7%
Q2 2024Aug 12, 2024 · Before open−12.9%
All 17 quarters
QuarterResultsShare move
Q1 2024May 9, 2024+2.2%
Q4 2023Mar 19, 2024 · Before open+2.1%
Q3 2023Nov 8, 2023 · Before open−0.1%
Q2 2023Aug 8, 2023 · Before open+1.3%
Q1 2023May 10, 2023 · Before open+1.9%
Q4 2022Mar 29, 2023 · After close−4.5%
Q3 2022Dec 30, 2022 · After close−1.9%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck25 slidesOctober 2026
Investor Presentation (September 2026)Investor deck25 slidesSeptember 2026
Investor Presentation (August 2026)Investor deck25 slidesAugust 2026
Investor Presentation (July 2026)Investor deck18 slidesJuly 2026
Investor Presentation (June 2026)Investor deck36 slidesJune 2026
Investor Presentation (May 2026)Investor deck36 slidesMay 2026
Investor Presentation (April 2026)Investor deck36 slidesApril 2026
Investor Presentation (March 2026)Investor deck36 slidesMarch 2026
Investor Presentation (February 2026)Investor deck34 slidesFebruary 2026
Investor Presentation (January 2026)Investor deck43 slidesJanuary 2026
All 24 decks
DeckKindSlidesDate
Investor Presentation (July 2025)Investor deck54 slidesJuly 2025
Investor Presentation (March 2025)Investor deck40 slidesMarch 2025
Investor Presentation (January 2025)Investor deck37 slidesJanuary 2025
Clinical Trials on Alzheimer's Disease Conference (CTAD24) 2024Conference16 slidesOct 29, 2024
Investor Presentation (April 2024)Investor deck38 slidesApril 2024
Investor Presentation (February 2024)Investor deck37 slidesFebruary 2024
5th Exosome Based Therapeutics Summit (November 2023)Conference25 slidesNov 8, 2023
Investor Presentation (October 2023)Investor deck31 slidesOctober 2023
Technical Presentation (June 2023)Technical9 slidesJun 7, 2023
Investor Presentation (June 2023)Investor deck31 slidesJune 2023
Investor Presentation (May 2023)Investor deck24 slidesMay 2023
Investor Presentation (May 2023)Investor deck29 slidesMay 2023
2023 MDA Clinical & Scientific ConferenceConference18 slidesMar 21, 2023
IPO Roadshow (December 2022)IPO roadshow25 slidesDec 6, 2022

Open Decks

Financings

RaiseDate
Private placement of common stock
Announced: about US$11.1M · US$4.4 a share
Buyers: Dr. Reddy’s Laboratories, Inc. ($10 million); Greenlight Capital ($1.1 million)
Use of proceeds: Accelerate tech transfer and scale-up manufacturing of low dose IL-2 to support commercial readiness of COYA 302
Jan 30, 2026
Public offering of common stock
Closed: US$23M raised · US$5.5 a share · Lucid Capital Markets +1
Dealers: Lucid Capital Markets (lead), Allele Capital Partners, LLC
Use of proceeds: Working capital and general corporate purposes, including funding its clinical development plan
Oct 27, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$5.00 a share on Dec 28, 2022.

Price
US$5.00 a share
Shares offered
3,050,000 shares of common stock
Offering size
US$15.3 million
Underwriters' option
Up to 290,000 more shares
Listing
COYA on the Nasdaq Capital Market
Underwriters
Chardan, Newbridge Securities Corporation, Joseph Gunnar & Co., LLC · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceAug 19, 2022
Filed publiclyNov 18, 2022
Amended twiceNewest Dec 13, 2022
Shares registered with an exchangeDec 27, 2022
Declared effective by the SECDec 28, 2022
Final prospectus, with the priceDec 30, 2022

Open IPO · From the cover of the final prospectus (424B4) filed Dec 30, 2022

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Revenue7.95M3.55M6.00M00
Cost of revenue27.4K11.9M5.50M4.41M16.1K
Gross profit7.92M-8.31M500.7K-4.41M-16.1K
Research and development16.7M11.9M5.50M4.41M2.54M373.5K
Selling, general and administrative11.4M8.89M7.83M4.85M2.31M668.7K
Operating income-22.6M-17.2M-7.90M-9.81M-4.87M-1.04M
Depreciation and amortization27.4K27.4K27.4K27.4K16.1K704.7K
EBITDA-22.5M-17.2M-7.88M-9.78M-4.85M-337.5K
Interest expense2.43M21.5K39.0K
Income before tax-21.2M-15.6M-7.26M-12.2M-4.89M-1.10M
Income tax3.09K-720.3K723.9K0-21.5K-704
Net income-21.2M-14.9M-7.99M-12.2M-4.89M-1.10M
Earnings per share, basic-1.27-0.98-0.79-4.73-1.89-0.42
Earnings per share, diluted-1.27-0.98-0.79-4.73-1.89

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents46.8M38.3M32.6M5.93M4.34M8.72M
Short-term investments38.3B
Receivables730.6K7.50M1.00K
Current assets49.9M44.3M41.2M7.18M4.58M8.75M
Property, plant and equipment11.2K38.6K65.9K93.3K120.7K
Total assets50.0M44.3M41.3M8.40M4.79M8.75M
Accounts payable1.06M1.59M1.16M1.82M857.6K447.1K
Current liabilities5.87M3.82M5.05M3.82M1.15M447.1K
Long-term debt13.0M
Total debt13.0M
Total liabilities6.92M4.77M5.63M16.8M1.15M447.1K
Shareholders' equity43.0M39.6M35.6M-8.39M3.64M8.30M
Shares outstanding20.9M16.7M14.4M2.59M2.59M2.59M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-10.7M-10.3M-11.2M-7.24M-3.90M-391.3K
Capital spending00-1-4-136.8K-4
Free cash flow-10.7M-10.3M-11.2M-7.24M-4.04M-391.3K
Cash from investing-1.16M-25.0K-543.2K-525.0K-136.8K-136.8K
Cash from financing20.4M16.0M38.4M9.36M-340.6K9.11M
Change in cash8.48M5.71M26.7M1.59M-4.38M8.72M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
8-K · Current reportNov 10, 2026ResultsSEC
8-K · Current reportOct 14, 2026Current reportSEC
8-K · Current reportOct 5, 2026Current reportSEC
8-K · Current reportSep 15, 2026Current reportSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
8-K · Current reportAug 11, 2026ResultsSEC
8-K/A · Current report, amendedAug 7, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 27, 2026Big-stake noticeSEC
8-K · Current reportJun 25, 2026Meeting outcomeSEC
Show 200 filings
FilingDateTypeFiled with
ARS · Annual report to shareholdersMay 13, 2026Annual reportSEC
DEFA14A · Additional proxy materialMay 13, 2026Meeting noticeSEC
DEF 14A · Proxy statementMay 13, 2026Meeting noticeSEC
8-K · Current reportMay 12, 2026Material contractSEC
424B5 · ProspectusMay 12, 2026Offer documentSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
8-K · Current reportMay 12, 2026ResultsSEC
4 · Change in ownershipApr 9, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 9, 2026Insider tradeSEC
8-K · Current reportApr 2, 2026Management or board changeSEC
EFFECT · Notice that a registration is effectiveMar 23, 2026Other filingsSEC
424B3 · ProspectusMar 20, 2026Offer documentSEC
CORRESP · Letter to the SECMar 19, 2026Other filingsSEC
UPLOAD · Letter from the SECMar 19, 2026Other filingsSEC
S-3 · Registration statementMar 16, 2026Offer documentSEC
10-K · Annual reportMar 16, 2026Annual reportSEC
8-K · Current reportMar 16, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeMar 12, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 30, 2026Big-stake noticeSEC
8-K · Current reportJan 30, 2026Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 28, 2026Big-stake noticeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
8-K · Current reportJan 20, 2026Current reportSEC
8-K · Current reportJan 8, 2026Current reportSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
8-K · Current reportDec 17, 2025Current reportSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
8-K · Current reportOct 27, 2025Material contractSEC
424B5 · ProspectusOct 27, 2025Offer documentSEC
424B5 · ProspectusOct 23, 2025Offer documentSEC
8-K · Current reportSep 2, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveAug 20, 2025Other filingsSEC
424B7 · ProspectusAug 19, 2025Offer documentSEC
4 · Change in ownershipAug 19, 2025Insider tradeSEC
CORRESP · Letter to the SECAug 18, 2025Other filingsSEC
UPLOAD · Letter from the SECAug 13, 2025Other filingsSEC
S-3 · Registration statementAug 12, 2025Offer documentSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
8-K · Current reportJul 29, 2025Current reportSEC
8-K · Current reportJul 1, 2025Current reportSEC
8-K · Current reportJun 26, 2025Meeting outcomeSEC
ARS · Annual report to shareholdersMay 16, 2025Annual reportSEC
DEFA14A · Additional proxy materialMay 16, 2025Meeting noticeSEC
DEF 14A · Proxy statementMay 16, 2025Meeting noticeSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
8-K · Current reportMay 13, 2025ResultsSEC
10-K/A · Annual report, amendedApr 28, 2025Annual reportSEC
10-K · Annual reportMar 18, 2025Annual reportSEC
8-K · Current reportMar 18, 2025ResultsSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 10, 2025Big-stake noticeSEC
S-8 · Registration statement for employee plansJan 30, 2025Offer documentSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveDec 2, 2024Other filingsSEC
424B3 · ProspectusNov 29, 2024Offer documentSEC
CORRESP · Letter to the SECNov 26, 2024Other filingsSEC
UPLOAD · Letter from the SECNov 25, 2024Other filingsSEC
S-3 · Registration statementNov 20, 2024Offer documentSEC
4 · Change in ownershipNov 14, 2024Insider tradeSEC
4 · Change in ownershipNov 13, 2024Insider tradeSEC
4 · Change in ownershipNov 12, 2024Insider tradeSEC
4 · Change in ownershipNov 12, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2024Quarterly reportSEC
8-K · Current reportNov 6, 2024ResultsSEC
8-K · Current reportNov 5, 2024Management or board changeSEC
SC 13G/A · Big-stake notice, amendedNov 4, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 4, 2024Big-stake noticeSEC
8-K · Current reportOct 31, 2024Management or board changeSEC
8-K · Current reportOct 29, 2024Current reportSEC
DOct 28, 2024Other filingsSEC
8-K · Current reportOct 22, 2024Material contractSEC
3 · Initial statement of ownershipAug 20, 2024Insider tradeSEC
8-K · Current reportAug 19, 2024Management or board changeSEC
10-Q · Quarterly reportAug 12, 2024Quarterly reportSEC
8-K · Current reportAug 12, 2024ResultsSEC
8-K · Current reportJul 15, 2024Current reportSEC
424B3 · ProspectusJun 24, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveJun 24, 2024Other filingsSEC
CORRESP · Letter to the SECJun 20, 2024Other filingsSEC
UPLOAD · Letter from the SECJun 18, 2024Other filingsSEC
S-3 · Registration statementJun 14, 2024Offer documentSEC
4 · Change in ownershipJun 5, 2024Insider tradeSEC
4 · Change in ownershipJun 5, 2024Insider tradeSEC
4 · Change in ownershipJun 5, 2024Insider tradeSEC
8-K · Current reportJun 5, 2024Material contractSEC
8-K · Current reportMay 20, 2024Material contractSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
8-K · Current reportMay 9, 2024ResultsSEC
8-K · Current reportMay 8, 2024Management or board changeSEC
DEFA14A · Additional proxy materialMar 28, 2024Meeting noticeSEC
ARS · Annual report to shareholdersMar 28, 2024Annual reportSEC
DEFA14A · Additional proxy materialMar 28, 2024Meeting noticeSEC
DEF 14A · Proxy statementMar 28, 2024Meeting noticeSEC
10-K · Annual reportMar 19, 2024Annual reportSEC
8-K · Current reportMar 19, 2024ResultsSEC
4 · Change in ownershipMar 5, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 7, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 2, 2024Insider tradeSEC
4 · Change in ownershipFeb 2, 2024Insider tradeSEC
4 · Change in ownershipFeb 2, 2024Insider tradeSEC
4 · Change in ownershipJan 19, 2024Insider tradeSEC
4 · Change in ownershipJan 19, 2024Insider tradeSEC
4 · Change in ownershipJan 19, 2024Insider tradeSEC
4 · Change in ownershipJan 19, 2024Insider tradeSEC
4 · Change in ownershipJan 19, 2024Insider tradeSEC
8-K · Current reportJan 19, 2024Current reportSEC
424B3 · ProspectusJan 16, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 16, 2024Other filingsSEC
CORRESP · Letter to the SECJan 10, 2024Other filingsSEC
UPLOAD · Letter from the SECJan 9, 2024Other filingsSEC
S-3 · Registration statementJan 4, 2024Offer documentSEC
4 · Change in ownershipJan 4, 2024Insider tradeSEC
3 · Initial statement of ownershipDec 29, 2023Insider tradeSEC
DDec 20, 2023Other filingsSEC
8-K · Current reportDec 20, 2023Management or board changeSEC
SC 13G · Big-stake noticeDec 12, 2023Big-stake noticeSEC
8-K · Current reportDec 6, 2023Material contractSEC
10-Q · Quarterly reportNov 8, 2023Quarterly reportSEC
8-K · Current reportNov 8, 2023ResultsSEC
4 · Change in ownershipAug 21, 2023Insider tradeSEC
3 · Initial statement of ownershipAug 21, 2023Insider tradeSEC
8-K · Current reportAug 21, 2023Management or board changeSEC
10-Q · Quarterly reportAug 8, 2023Quarterly reportSEC
8-K · Current reportAug 8, 2023ResultsSEC
4 · Change in ownershipJul 19, 2023Insider tradeSEC
3 · Initial statement of ownershipJul 19, 2023Insider tradeSEC
8-K · Current reportJul 14, 2023Management or board changeSEC
8-K · Current reportJul 10, 2023Management or board changeSEC
8-K · Current reportJun 29, 2023Meeting outcomeSEC
8-K · Current reportJun 12, 2023Current reportSEC
8-K · Current reportMay 23, 2023Current reportSEC
DEFA14A · Additional proxy materialMay 19, 2023Meeting noticeSEC
ARS · Annual report to shareholdersMay 19, 2023Annual reportSEC
DEF 14A · Proxy statementMay 19, 2023Meeting noticeSEC
8-K · Current reportMay 16, 2023Current reportSEC
424B4 · ProspectusMay 12, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveMay 11, 2023Other filingsSEC
10-Q · Quarterly reportMay 10, 2023Quarterly reportSEC
8-K · Current reportMay 10, 2023ResultsSEC
POS AM · Amendment to an effective registrationMay 8, 2023Offer documentSEC
10-K/A · Annual report, amendedMay 1, 2023Annual reportSEC
S-8 · Registration statement for employee plansApr 14, 2023Offer documentSEC
10-K · Annual reportMar 29, 2023Annual reportSEC
8-K · Current reportMar 29, 2023ResultsSEC
8-K · Current reportMar 22, 2023Material contractSEC
8-K · Current reportMar 21, 2023Current reportSEC
8-K · Current reportMar 13, 2023Current reportSEC
8-K · Current reportMar 1, 2023Management or board changeSEC
4 · Change in ownershipMar 1, 2023Insider tradeSEC
4 · Change in ownershipMar 1, 2023Insider tradeSEC
4 · Change in ownershipMar 1, 2023Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 14, 2023Big-stake noticeSEC
8-K · Current reportJan 25, 2023Current reportSEC
4/A · Change in ownership, amendedJan 17, 2023Insider tradeSEC
SC 13G · Big-stake noticeJan 5, 2023Big-stake noticeSEC
4 · Change in ownershipJan 4, 2023Insider tradeSEC
4 · Change in ownershipJan 4, 2023Insider tradeSEC
4 · Change in ownershipJan 4, 2023Insider tradeSEC
4 · Change in ownershipJan 4, 2023Insider tradeSEC
4 · Change in ownershipJan 4, 2023Insider tradeSEC
4 · Change in ownershipJan 4, 2023Insider tradeSEC
4 · Change in ownershipJan 4, 2023Insider tradeSEC
424B4 · ProspectusDec 30, 2022Offer documentSEC
CERT · Exchange's certificate of listingDec 29, 2022Other filingsSEC
SEC STAFF LETTERDec 29, 2022Other filingsSEC

This page holds 200 of 232 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Coya Therapeutics, Inc.’s releases · as of Nov 5, 2026

Common shares
23,457,849
Fully diluted
23,457,849

Fully diluted

LineSharesAs of
Common shares23,457,849Nov 5, 2026

Share count over time

CountShares
Nov 5, 202623,457,849
Sep 30, 202623,457,849

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
DME Capital Management, LP2.34M10.0%US$11.7MSep 30, 2026
Vanguard988K4.2%US$4.95MSep 30, 2026
AIGH Capital Management LLC632K2.7%US$3.17MSep 30, 2026
Alyeska Investment Group, L.P.400K1.7%US$2MSep 30, 2026
CM Management, LLC400K1.7%US$2MSep 30, 2026
Private Management Group Inc381K1.6%US$1.91MSep 30, 2026
Marshall Wace, LLP324K1.4%US$1.62MSep 30, 2026
Prosight Management, LP230K0.98%US$1.15MSep 30, 2026
Geode Capital211K0.90%US$1.06MSep 30, 2026
Dimensional169K0.72%US$849KSep 30, 2026
All 50 holders
HolderSharesOf the companyValueAs of
Renaissance Technologies122K0.52%US$610KSep 30, 2026
Prelude Capital Management, LLC102K0.43%US$510KSep 30, 2026
Jones Financial Companies Lllp100K0.43%US$509KSep 30, 2026
JBF Capital, Inc.100K0.43%US$501KSep 30, 2026
BlackRock98,5960.42%US$494KSep 30, 2026
RBC83,9000.36%US$420KSep 30, 2026
State Street79,8130.34%US$400KSep 30, 2026
Prudential Financial Inc79,7010.34%US$399KSep 30, 2026
Morgan Stanley77,7000.33%US$389KSep 30, 2026
Susquehanna64,1440.27%US$321KSep 30, 2026
Goldman Sachs46,4210.20%US$233KSep 30, 2026
Northern Trust45,0720.19%US$226KSep 30, 2026
ADAR1 Capital Management, LLC40,9000.17%US$205KSep 30, 2026
Long Corridor Asset Management Ltd38,7660.17%US$194KSep 30, 2026
UBS34,4950.15%US$173KSep 30, 2026
Jane Street28,4950.12%US$143KSep 30, 2026
GHP Investment Advisors, Inc.26,1710.11%US$131KSep 30, 2026
XTX Topco Ltd21,1020.09%US$106KSep 30, 2026
Northwestern Mutual Wealth Management Co20,6260.09%US$103KSep 30, 2026
Axq Capital, LP15,9270.07%US$79,794Sep 30, 2026
Mercer Global Advisors Inc12,3200.05%US$61,723Sep 30, 2026
American Century11,2180.05%US$56,202Sep 30, 2026
Raymond James Financial Inc10,2250.04%US$51,227Sep 30, 2026
HighTower Advisors, LLC10,0290.04%US$50,245Sep 30, 2026
Schwab10,0000.04%US$50,100Sep 30, 2026
First Dallas Securities Inc.10,0000.04%US$50,100Sep 30, 2026
JPMorgan5,0040.02%US$25,170Sep 30, 2026
BNP Paribas4,7630.02%US$23,863Sep 30, 2026
Bfsg, LLC3,4550.01%US$17,310Sep 30, 2026
Tower Research Capital LLC (TRC)3,2170.01%US$16,117Sep 30, 2026
Rockefeller Capital Management L.P.2,000<0.01%US$10,020Sep 30, 2026
Allworth Financial LP1,000<0.01%US$5,010Sep 30, 2026
SBI Securities Co., Ltd.820<0.01%US$4,108Sep 30, 2026
Wells Fargo500<0.01%US$2,505Sep 30, 2026
North Star Investment Management Corp.340<0.01%US$1,703Sep 30, 2026
Superior Planning, LLC315<0.01%US$1,578Sep 30, 2026
Arax Advisory Partners190<0.01%US$952Sep 30, 2026
Triumph Capital Management50<0.01%US$250Sep 30, 2026
Caitong International Asset Management Co., Ltd35<0.01%US$175Sep 30, 2026
Barclays3<0.01%US$15Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund601K2.6%US$3.52MJun 30, 2026
Vanguard Extended Market Index Fund220K0.94%US$1.29MJun 30, 2026
Fidelity Extended Market Index Fund109K0.46%US$524KMay 31, 2026
Dimensional U.S. Small Cap ETF75,5580.32%US$317KJul 31, 2026
iShares Micro-Cap ETF65,9090.28%US$386KJun 30, 2026
U.S. Micro Cap Portfolio37,1580.16%US$156KJul 31, 2026
Fidelity Series Total Market Index Fund33,4380.14%US$161KMay 31, 2026
Fidelity Total Market Index Fund24,0660.10%US$116KMay 31, 2026
Fidelity Nasdaq Composite Index Fund14,8920.06%US$71,779May 31, 2026
U.S. Small Cap Portfolio13,1070.06%US$54,918Jul 31, 2026
All 22 holders
HolderSharesOf the companyValueAs of
Vanguard Balanced Index Fund10,9020.05%US$63,777Jun 30, 2026
Vanguard Institutional Total Stock Market Index Fund10,2460.04%US$59,939Jun 30, 2026
Schwab Total Stock Market Index Fund10,0000.04%US$41,900Jul 31, 2026
Dimensional US Vector Equity ETF4,7930.02%US$20,083Jul 31, 2026
1290 VT Micro Cap Portfolio4,4350.02%US$25,945Jun 30, 2026
U.S. Vector Equity Portfolio3,5060.01%US$14,690Jul 31, 2026
U.S. Core Equity 2 Portfolio3,4940.01%US$14,640Jul 31, 2026
Dimensional US Core Equity 1 ETF2,8450.01%US$11,921Jul 31, 2026
Victory Extended Market Index Fund2,312<0.01%US$9,687Jul 31, 2026
Dimensional U.S. Core Equity 2 ETF1,977<0.01%US$8,284Jul 31, 2026
U.S. Core Equity 1 Portfolio1,715<0.01%US$7,186Jul 31, 2026
Dimensional US Sustainability Core 1 ETF137<0.01%US$574Jul 31, 2026

Big stakes

StakeStakeSharesDateFiling
DME Capital Management, LP9.90%1.65MDec 31, 2024Schedule 13G
Dr. Reddy's Laboratories, Inc.9.70%2.27MJan 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Wilbur L Ross Jr
Other companies: Taronis Fuels Inc (Director · Jun 4, 2021 – Jun 4, 2021 · Past); Ross Acquisition II Corp (Chief Executive Officer, Director · Mar 11, 2021 – Mar 11, 2021 · Past)
Director · Since at least Dec 19, 2023
David Snyder
Other companies: Exicure, Inc. (Chief Financial Officer · Mar 12, 2020 – Mar 12, 2020 · Past)
Chief Financial Officer & Chief Operating Officer · Since at least Dec 28, 2022
Hideki Garren
Other companies: Prothena Corporation plc (Chief Medical Officer · Apr 5, 2021 – Feb 27, 2024 · Past)
Director · Dec 28, 2022 – Jan 1, 2024 · Past
Adrian HepnerChief Medical Officer · Dec 28, 2022 – Feb 27, 2023 · Past
Anabella VillalobosDirector · Since at least Jan 2, 2026
Ann LeeDirector · Since at least Aug 22, 2023
Arun SwaminathanChief Executive Officer, Director · Since at least Aug 19, 2024
Daniel BarvinVice President of Operations & Patient Advocacy · Since at least Nov 4, 2026
Dieter WeinandChairman of the Board of Directors · Since at least Apr 2, 2026
Dov GoldsteinUntil Jun 18, 2026 · Past
All 16 people
PersonSeat
Fred GrossmanChief Medical Officer · Since at least Jan 22, 2026
Fred GrossmanPresident & Chief Medical Officer · Since at least Oct 28, 2026
Karen KingSenior VP of Program Management & Clinical Operations · Since at least Oct 28, 2026
Mark PavaoDirector · Since at least Apr 1, 2026
Michelle FrazierSenior VP of Regulatory · Since at least Nov 4, 2026
Wilbur RossDirector · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Coya Therapeutics, Inc.